The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday. WHY ...

When the mail-in ancestry company 23andMe filed for bankruptcy, Regeneron Pharmaceuticals stepped in to snap it up. Though in the end the Tarrytown-based company was outbid, the scenario raised a ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...

A judge has finally approved the bankruptcy sale of 23andme, and its data, to a nonprofit owned by 23andme's founder. That means that if you have data stored with the site, it's basically staying in ...

Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, outbid Regeneron ...

23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. Stream Connecticut News for free, 24/7 ...

New York and other states filed a lawsuit seeking to block 23andMe, the bankrupt genetic testing firm, from selling millions of Americans' genetic data to the highest bidder. A total of 28 state ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, Inc. tops our list for being one of the most undervalued healthcare stocks ...